A phase 3 trial suggest that upadacitinib, a JAK inhibitor, may help patients with moderately to severely active ulcerative colitis obtain long-term control of the condition.

中文翻译：

---

控制溃疡性结肠炎

一项 3 期试验表明，一种 JAK 抑制剂 upadacitinib 可以帮助中度至重度活动性溃疡性结肠炎患者获得长期的病情控制。